VistaGen Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
VistaGen Therapeutics, Inc. carries a market capitalization of 18.36M, placing it among publicly traded companies globally. Its enterprise value stands at -36.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 18.36M |
| Enterprise Value | -36.09M |
Share Statistics
VistaGen Therapeutics, Inc. currently has 39.62M shares outstanding.
| Shares Outstanding | 39.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 30.70, and the price-to-book ratio stands at -0.05.
| PE Ratio | N/A |
| PS Ratio | 30.70 |
| PB Ratio | -0.05 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | -0.40 |
| P/OCF Ratio | -0.40 |
Enterprise Valuation
| EV / Sales | 76.27 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
VistaGen Therapeutics, Inc. maintains a current ratio of 4.67, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.67 |
| Quick Ratio | 4.57 |
| Debt / Equity | 2.80 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -85.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
VistaGen Therapeutics, Inc.'s stock has declined approximately -76.56485% over the past 52 weeks. The 50-day moving average sits at 0.61, while the 200-day moving average is 2.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -76.56485% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 2.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, VistaGen Therapeutics, Inc. generated 790,000.00 in revenue and converted that into -67.05M in net income, yielding earnings per share of -1.83. EBITDA reached -69.19M, while operating income came in at -69.90M.
| Revenue | 790,000.00 |
| Gross Profit | N/A |
| Operating Income | -69.90M |
| Pretax Income | -67.05M |
| Net Income | -67.05M |
| EBITDA | -69.19M |
| EBIT | -69.90M |
| Earnings Per Share (EPS) | -1.83 |
Balance Sheet
VistaGen Therapeutics, Inc. holds 61.77M in cash and equivalents against 1.43M in total debt, resulting in a net debt position of -46.99M. Total book value stands at -461.00M, with working capital of 49.72M providing operational flexibility.
| Cash & Cash Equivalents | 61.77M |
| Total Debt | 1.43M |
| Net Debt | -46.99M |
| Equity (Book Value) | -461.00M |
| Book Value Per Share | -12.58 |
| Working Capital | 49.72M |
Cash Flow
VistaGen Therapeutics, Inc. produced -60.30M in operating cash flow over the past twelve months. After subtracting -239,000.00 in capital expenditures, free cash flow totaled -60.54M - equivalent to -1.65 per share.
| Operating Cash Flow | -60.30M |
| Capital Expenditures | -239,000.00 |
| Free Cash Flow | -60.54M |
| FCF Per Share | -1.65 |
Margins
VistaGen Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -8,847.85 and net profit margin of -8,486.84 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -8,847.85 |
| Pretax Margin | -8,486.84 |
| Profit Margin | -8,486.84 |
| EBITDA Margin | -8,758.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -136.92 |
| FCF Yield | -247.66 |
Stock Splits
VistaGen Therapeutics, Inc.'s most recent stock split took place on June 7, 2023 with a 30:1 split ratio.
| Last Split Date | 6/7/2023 |
| Split Ratio | 30:1 |
Scores
VistaGen Therapeutics, Inc. posts an Altman Z-Score of -11.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.51 |